UK – NICE backs Rozlytrek for subset of NSCLC patients

NICE has published final draft guidance backing NHS use of Roche's Rozlytrek (entrectinib) as a treatment option for ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.

ROS1 is a rare mutation found in fewer than 2% of NSCLC cases, for which there is currently a lack of treatment options, especially for those patients where the disease has spread to the brain.

In clinical trials, Rozlytrek was shown to be effective at shrinking tumours and holding back overall disease progression (median of 16.8 months progression-free), including in patients who have developed brain tumours, NICE noted…